Advertisement

Cardiology

Home Cardiology
Fenofibrate therapy may reduce cardiovascular disease in statin-treated patients with diabetes and dyslipidemia

Fenofibrate May Reduce CVD in Patients With DM, Dyslipidemia

No reduction in primary outcome for 4,644 ACCORD participants followed for median of 9.7 years
For patients with chronic kidney disease

Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD

Reduced all-cause death for chronic kidney disease, congestive heart failure, chronic liver disease
Anterior T-wave inversion occurs in 2.3 percent of young asymptomatic adults

Anterior T-Wave Inversion in 2.3 Percent of Healthy Young Adults

Seen in 2.3 percent of asymptomatic individuals; mainly occurs in leads V1 and V2
For adults aged 80 years and older without comorbidity

SBP <135 mm Hg Tied to Greater Mortality in Elderly With HTN

Findings in the oldest adults with hypertension and free from comorbidities
Too few American young adults are receiving needed statin medications

Too Few U.S. Young Adults Being Prescribed Needed Statins

Guidelines suggest medications could help prevent CVD, but many younger people missing out
For the seventh year in a row

DASH Tops the 2017 Rankings for Best Diets

U.S. News & World Report ranks Mediterranean diet as second, up from fourth place
Mid upper arm circumference is an independent predictor of survival in older adults with cardiovascular disease

Arm Circumference May Be Useful Predictor of CVD Survival

Findings among elderly patients with cardiovascular disease
There is a greater reduction in readmission rates at hospitals subject to penalties under the Affordable Care Act's Hospital Readmission Reduction Program

Greater Drop in Readmissions With ACA Program Penalties

Greater reductions in readmission rates compared with those at non-penalized hospitals
Alcohol abuse increases the risk of atrial fibrillation

Alcohol Abuse Ups Risk of Several Heart Conditions

Alcohol abuse of similar magnitude to other well-recognized modifiable risk factors
Conventional clinical trials are unable to detect clinically important heterogeneity in intensive blood pressure treatment effects

Conventional Trials Can’t Detect Heterogeneity in BP Tx Effects

Clinically important heterogeneity in intensive BP tx effect can be ID'd in sequential randomization trials